Brunner-La Rocca H P, Schindler R, Schlumpf M, Saller R, Suter M
Interdisciplinary Clinical Research Unit, University Hospital, Basel, Switzerland.
Vasa. 2005 Feb;34(1):11-7. doi: 10.1024/0301-1526.34.1.11.
Previous studies showed an anti-atherosclerotic effect of PADMA 28, an herbal formula based on Tibetan medicine. As the mechanisms of action are not fully understood, we investigated whether PADMA 28 may lower blood lipids and lipid oxidisability, and affect early endothelial dysfunction.
Sixty otherwise healthy subjects with total cholesterol > or = 5.2 mmol/l and < 8.0 mmol/l were randomly assigned to placebo or PADMA 28, 3 x 2 capsules daily, for 4 weeks (double-blind). Blood lipids (total, LDL-, and HDL-cholesterol, triglycerides, Apo-lipoprotein A1 and B) and ex vivo lipid oxidisability were measured before and after treatment. In a subset of 24 subjects, endothelial function was assessed using venous occlusion plethysmography with intraarterial infusion of acetylcholine. Isolated LDL and plasma both untreated and pre-treated with PADMA 28 extract were oxidised by the radical generator AAPH. Conjugated diene formation was measured at 245 nm.
Blood lipids did not change during the study in both groups. In contrast to previous reports in mild hypercholesterolaemia, no endothelial dysfunction was seen and, consequently, was not influenced by therapy. Ex vivo blood lipid oxidisability was significantly reduced with PADMA 28 (area undercurve: 5.29 +/- 1.62 to 4.99 +/- 1.46, p = 0.01), and remained unchanged in the placebo group (5.33 +/- 1.88 to 5.18 +/- 1.78, p > 0. 1). This effect persisted one week after cessation of medication. In vitro experiments confirmed the prevention of lipid peroxidation in the presence of PADMA 28 extracts. Persistent protection was also seen for LDL isolated from PADMA 28-pretreated blood after being subjected to rigorous purification.
This study suggests that the inhibition of blood lipid oxidisability by PADMA 28 may play a role in its anti-atherosclerotic effect.
先前的研究表明，藏药配方帕德玛28具有抗动脉粥样硬化作用。由于其作用机制尚未完全明确，我们研究了帕德玛28是否能降低血脂和脂质氧化能力，并影响早期内皮功能障碍。
60名总胆固醇≥5.2 mmol/l且<8.0 mmol/l的健康受试者被随机分为安慰剂组或帕德玛28组，每天服用3次，每次2粒胶囊，持续4周（双盲）。在治疗前后测量血脂（总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、载脂蛋白A1和B）和体外脂质氧化能力。在24名受试者的亚组中，使用静脉阻塞体积描记法并动脉内注射乙酰胆碱来评估内皮功能。用自由基发生器AAPH氧化未处理和用帕德玛28提取物预处理的分离低密度脂蛋白和血浆。在245 nm处测量共轭二烯的形成。
两组研究期间血脂均未变化。与先前关于轻度高胆固醇血症的报道不同，未观察到内皮功能障碍，因此也不受治疗影响。帕德玛28显著降低了体外血脂氧化能力（曲线下面积：5.29±1.62至4.99±1.46，p = 0.01），而安慰剂组保持不变（5.33±1.88至5.18±1.78，p>0.1）。停药一周后这种作用仍然存在。体外实验证实了帕德玛28提取物存在时对脂质过氧化的预防作用。对从帕德玛28预处理血液中分离出的低密度脂蛋白进行严格纯化后，也观察到了持续的保护作用。
本研究表明，帕德玛28对血脂氧化能力的抑制作用可能在其抗动脉粥样硬化作用中发挥作用。
Zotero 插件